An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a new study shows.
Health Professionals
TCR CDR3s and renalase-1 linked to increased melanoma survival
A new research paper titled “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival" has been published in Oncotarget.
Cancer Vaccine for NSCLC and Melanoma Could Be Paradigm-Changing
The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.
Individualized cancer therapy demonstrates safety and sustained immune responses
For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells.